Faculty

Molecular Biomedicine Lab (MBL) is a global stem cell research group that has a network with Max Planck Institute, the world-leading research institute. MBL aims to develop novel stem cell technologies to treat incurable disease. Direct conversion is a technology that can generate target cells from skin cells by bypassing the pluripotent stage thereby solving the tumorigenic risk of pluripotent stem cells. MBL focuses on developing stem cell treatments that repair damaged tissues or damaged organs using patient-specific stem cells generated by direct conversion technology, organoid technology or stem cell-based tissues produced by 3D bio-printing technology.